Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

13.3%

2 terminated/withdrawn out of 15 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

60%

9 trials in Phase 3/4

Results Transparency

1 of 12 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

8(61.5%)

Phase 2

4(30.8%)

Phase 4

1(7.7%)

13Total

Phase 3(8)

Phase 2(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT05117398Phase 3Recruiting

Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus

Role: collaborator

NCT04170309Completed

Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases

Role: lead

NCT02955004Completed

Electrical Cardioversion of Recent Onset Atrial Fibrillation - Silent Thromboembolic Events, Reverse Atrial Remodeling

Role: collaborator

NCT01174160Phase 3Completed

A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4)

Role: lead

NCT00989001Phase 3Terminated

A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

Role: lead

NCT01627106Phase 4Withdrawn

A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)

Role: lead

NCT00668759Phase 3Completed

A Phase III Superiority Study of Vernakalant vs Amiodarone in Subjects With Recent Onset Atrial Fibrillation

Role: lead

NCT00267930Phase 2Completed

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

Role: lead

NCT00526136Phase 2Completed

Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

Role: lead

NCT00281554Phase 3Completed

Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation

Role: collaborator

NCT00468767Phase 3Completed

Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation

Role: lead

NCT00476112Phase 2Completed

A Phase II/III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Flutter

Role: lead

NCT00115791Phase 3Completed

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Role: collaborator

NCT00125320Phase 3Completed

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

Role: collaborator

NCT00063687Phase 2Completed

Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure

Role: lead

All 15 trials loaded